J 2021

Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study

KAYSER, S., R. K. HILLS, R. LANGOVA, M. KRAMER, F. GUIJARRO et. al.

Basic information

Original name

Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study

Authors

KAYSER, S. (guarantor), R. K. HILLS, R. LANGOVA, M. KRAMER, F. GUIJARRO, Zuzana ŠUSTKOVÁ (203 Czech Republic, belonging to the institution), E. H. ESTEY, C. M. SHAW, Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Pavel ZAK (203 Czech Republic), M. R. BAER, A. M. BRUNNER, T. SZOTKOWSKI, Petr CETKOVSKY (203 Czech Republic), D. GRIMWADE, R. B. WALTER, A. K. BURNETT, A. D. HO, G. EHNINGER, C. MULLER-TIDOW, U. PLATZBECKER, C. THIEDE, C. ROLLIG, A. SCHULZ, G. WARSOW, B. BRORS, J. ESTEVE, N. H. RUSSELL, R. F. SCHLENK and M. J. LEVIS

Edition

British journal of haematology, England, Wiley-Blackwell, 2021, 0007-1048

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 8.615

RIV identification code

RIV/00216224:14110/21:00120102

Organization unit

Faculty of Medicine

UT WoS

000613871100001

Keywords in English

acute myeloid leukaemia; t(8;16)(p11;p13)/MYST3-CREBBP; whole-genome sequencing; allogeneic haematopoietic cell transplantation; outcome

Tags

Tags

International impact, Reviewed
Změněno: 7/6/2021 08:50, Mgr. Tereza Miškechová

Abstract

V originále

In acute myeloid leukaemia (AML) t(8;16)(p11;p13)/MYST3-CREBBP is a very rare abnormality. Previous small series suggested poor outcome. We report on 59 patients with t(8;16) within an international, collaborative study. Median age was 52 (range: 16-75) years. AML was de novo in 58%, therapy-related (t-AML) in 37% and secondary after myelodysplastic syndrome (s-AML) in 5%. Cytogenetics revealed a complex karyotype in 43%. Besides MYST3-CREBBP, whole-genome sequencing on a subset of 10 patients revealed recurrent mutations in ASXL1, BRD3, FLT3, MLH1, POLG, TP53, SAMD4B (n = 3, each), EYS, KRTAP9-1 SPTBN5 (n = 4, each), RUNX1 and TET2 (n = 2, each). Complete remission after intensive chemotherapy was achieved in 84%. Median follow-up was 5 center dot 48 years; five-year survival rate was 17%. Patients with s-/t-AML (P = 0 center dot 01) and those with complex karyotype (P = 0 center dot 04) had an inferior prognosis. Allogeneic haematopoietic cell transplantation (allo-HCT) was performed in 21 (36%) patients, including 15 in first complete remission (CR1). Allo-HCT in CR1 significantly improved survival (P = 0 center dot 04); multivariable analysis revealed that allo-HCT in CR1 was effective in de novo AML but not in patients with s-AML/t-AML and less in patients exhibiting a complex karyotype. In summary, outcomes of patients with t(8;16) are dismal with chemotherapy, and may be substantially improved with allo-HCT performed in CR1.

Links

NV15-25809A, research and development project
Name: Národní program studia mutací a klonality leukemických buněk u pacientů s akutní myeloidní leukémií